Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Nanda who wrote (10765)	4/24/1998 11:30:00 AM
From: Israel	Respond to of 34592

Xechem Announces U.S. Patent Application Allowance For Disposable Multi-Well Hexoid Plate Used For Identification And Culturing Of Microorganisms NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--April 24, 1998--Xechem International, Inc. (OTC BB:ZKEM), announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application directed to a multi-well disposable plate containing dehydrated media for identifying and culturing a variety of microorganisms. The multi-well culture plate has a cover with a centrally positioned aperture with channels radiating to positions directly over each well facilitating rehydration of the media and inoculation. The development of the multi-well hexoid plate was supported by the National Aeronautics and Space Administration (NASA) under SBIR Phase I Contract No. NAS9-18701. The intended use of the plate is for manned space vehicles so astronauts can culture specimens and determine susceptibility of microorganisms to antibiotics in a very brief time, within 24 hours. Once commercialized, the plate will be available to hospitals and diagnostic laboratories. According to Xechem's president, Dr. Ramesh Pandey, "We are very happy with the allowance of this patent, as these plates could have several applications in the diagnostics area, the veterinary field, and the developing countries. We hope to license this to a suitable company for commercialization." Xechem is engaged in the research, development and production of generic and proprietary drugs from natural sources, specializing in the development of difficult to replicate anti-cancer, antiviral (including AIDS), and antifungal compounds. The company also screens compounds for therapeutic action from China and India. For further information, contact Leonard Mudry (732) 247-3300. CONTACT: Leonard Mudry, 732/247-3300 KEYWORD: NEW JERSEY BW1153 APR 24,1998